Compare British American Tobacco PLC (BTI) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Cassava Sciences Inc — how do they compare? British American Tobacco PLC trades at $56 (market cap $122.36B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: British American Tobacco PLC is far larger — about 2562.5× Cassava Sciences Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BTI | FLNA | |
|---|---|---|
Market Cap | $122.36B | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $4.64 |
52-Week Low | $50.39 | $0.87 |
Enterprise Value | $166.31B | -$34.93M |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $57.05, down 3.84% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 24.99% net income margin and 13.33% ROE. Recent earnings show three beats out of four quarters, while cash flow turned negative in 2025. The company is pivoting to next-generation nicotine products like Velo, supported by a multi-year tech partnership with ITC Infotech announced in August 2026.
The outlook is mixed: valuation appears reasonable with a P/E of 14.48, and analyst consensus is 66.7% buy ratings, but technical indicators are bearish and regulatory risks persist. The stock offers income potential with dividends, yet faces headwinds from declining combustibles and recent workforce cuts.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
